Key result
Bisoprolol shows no benefit over carvedilol for 3-year composite outcomes after AMI with reduced LVEF.
Why the study?
Does bisoprolol improve the 3-year patient-oriented composite endpoint compared to carvedilol in patients with acute myocardial infarction and reduced LVEF undergoing PCI?
Observational (n=1,062)
Yes
Does bisoprolol improve the 3-year patient-oriented composite endpoint compared to carvedilol in patients with acute myocardial infarction and reduced LVEF undergoing PCI?
Bisoprolol and carvedilol demonstrated comparable 3-year cardiovascular outcomes in patients with acute myocardial infarction and reduced LVEF undergoing PCI.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
May support either agent for secondary prevention in AMI with reduced LVEF post-PCI; leaves open need for randomized confirmation.
BACKGROUND: Beta-blocker therapy remains a cornerstone in the management of acute myocardial infarction (AMI) with reduced left ventricular ejection fraction (LVEF). However, evidence comparing clinical outcomes among different β-blocker types is limited. This study compared the 3-year cardiovascular outcomes between bisoprolol and carvedilol in patients with AMI and reduced LVEF who underwent percutaneous coronary intervention (PCI). METHODS AND RESULTS: Data were derived from the Korean Acute Myocardial Infarction Registry V (KAMIR-V), a prospective nationwide multicenter registry. Among 16,521 enrolled patients, those who did not undergo PCI, had non-reduced or unknown LVEF, were not prescribed β-blockers, or received other β-blocker types were excluded. In all, 1,062 patients were classified according to the β-blocker prescribed at discharge (bisoprolol, n=386; carvedilol, n=676). The primary endpoint was the 3-year patient-oriented composite endpoint (POCE) of all-cause death, any myocardial infarction, or any revascularization. During a median follow-up of 1,076 days (interquartile range 732-1,109 days), POCE occurred in 18.9% of the bisoprolol group and 16.3% of the carvedilol group (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.54-1.17; P=0.237). After propensity score matching, results were consistent (HR 0.88; 95% CI 0.62-1.24; P=0.470). CONCLUSIONS: Among patients with AMI and reduced LVEF undergoing PCI, bisoprolol and carvedilol showed comparable 3-year cardiovascular outcomes. Both agents appear to be suitable options for secondary prevention in this high-risk population.
Jeong et al. (2026) conducted an observational in Acute myocardial infarction with reduced left ventricular ejection fraction (n=1,062). Bisoprolol vs. Carvedilol was evaluated on 3-year patient-oriented composite endpoint (POCE) of all-cause death, any myocardial infarction, or any revascularization (HR 0.79, 95% CI 0.54-1.17, p=0.237). Bisoprolol and carvedilol showed comparable 3-year rates of the patient-oriented composite endpoint among patients with acute myocardial infarction and reduced left ventricular ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: